Thus, targeted neutralization of CCR2 or blockade of CCL2 inhibited the recruitment of TAMS and monocytic MDSC at tumor sites, angiogenesis, cancer development, and metastasis in various cancer models, among them breast cancer, lung cancer, ovarian cancer, and others [74,75,76,77,78,79,80,81,82,83]. This evidence concerns the gene CCL2 and breast cancer.